Shareholders' Equity (Tables)

6 Months Ended

Jun. 30, 2022

Stockholders' Equity Note [Abstract]

Summary of comprehensive income (loss)

The following is a summary of comprehensive income (in millions):

	Three Months Ended June 30,						Six Months Ended June 30,
	2022			2021			2022			2021
Consolidated net income	$	49.7		$	58.7		$	111.8		$	116.5
Foreign currency translation adjustments		(76.9	)		14.3			(107.4	)		(53.6	)
Derivatives designated as hedging instruments, net of tax		41.5			0.4			62.6			48.8
Pension liability adjustments, net of tax		1.6			—			2.1			3.3
Comprehensive income		15.9			73.4			69.1			115.0
Less: Comprehensive income (loss) attributable to noncontrolling interests		(0.4	)		(0.7	)		(0.2	)		0.2
Less: Comprehensive loss attributable to redeemable noncontrolling interests		(0.5	)		—			(0.7	)		—
Comprehensive income attributable to Bruker Corporation	$	16.8		$	74.1		$	70.0		$	114.8

Summary of the components of accumulated other comprehensive income (loss), net of tax

The following is a summary of the components of accumulated other comprehensive income (loss) attributable to Bruker Corporation, net of tax (in millions):

	Foreign Currency Translation			Derivatives Designated as Hedging Instruments			Pension Liability Adjustment			Accumulated Other Comprehensive Income (Loss)
Balance at December 31, 2021	$	63.1		$	(40.1	)	$	(31.2	)	$	(8.2	)
Other comprehensive (loss) income before    reclassifications		(105.8	)		62.6			1.3			(41.9	)
Realized gain on amounts reclassified from other    comprehensive income		—			—			0.8			0.8
Net current period other comprehensive (loss) income		(105.8	)		62.6			2.1			(41.1	)
Balance at June 30, 2022	$	(42.7	)	$	22.5		$	(29.1	)	$	(49.3	)

Schedule of the impact of stock-based compensation expense

The Company recorded stock-based compensation expense as follows in the unaudited condensed consolidated statements of income and comprehensive income (in millions):

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Cost of product revenue	$	0.3	$	0.5	$	0.8	$	1.0
Selling, general and administrative		3.2		2.6		5.9		5.0
Research and development		0.3		0.5		0.9		1.0
Total stock-based compensation expense	$	3.8	$	3.6	$	7.6	$	7.0